ViiV Healthcare
393
25
49
281
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.7%
34 terminated/withdrawn out of 393 trials
89.2%
+2.7% vs industry average
28%
109 trials in Phase 3/4
52%
146 of 281 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (393)
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
Role: collaborator
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
Role: lead
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Role: collaborator
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
Role: lead
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
Role: lead
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
Role: lead
A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
Role: collaborator
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
Role: lead
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
Role: collaborator
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
Role: lead
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
Role: lead
First Time in Human Study of Long Acting VH4524184 Formulations
Role: lead
IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas
Role: collaborator
B/F/TAF to DTG/3TC Switch Study
Role: collaborator
Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone
Role: collaborator
A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
Role: lead
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Role: collaborator
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
Role: lead
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
Role: collaborator
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
Role: collaborator